

80/568761

IAP20 Rec'd PCT/PTO 21 FEB 2006

1/4

SEQUENCE LISTING

<110> Sumitomo Pharmaceuticals Co., Ltd.
<120> Method of preventing or treating inflammatory bowel diseases containing as the ingredient CD81 antibodies
<130> 533734
<150> JP 2003-304264
<151> 2003-08-28
<160> 2
<170> PatentIn version 3.2
<210> 1
<211> 1332
<212> DNA
<213> Homo sapiens
<400> 1
ccggccgcg ccccgaggc cgccccgcg ccgcgcgc atggagatgg agggctgcac 60
caagtgcattt aagtacctgc tcttcgtctt caatttcgtc ttctggctgg ctggaggcgt 120
gatcctgggt gtggccctgt ggctccgcga tgaccgcag accaccaacc tcctgttatct 180
ggagctggga gacaagccccg cgcccaacac cttctatgtt ggcatttata tcctcatcgc 240
tgtggcgct gtcattatgtt tcgttggctt cctggctgc tacggggcca tccaggaatc 300
ccagtgccctg ctggggacgt tcttcacactg cctgggtcatc ctgtttgcct gtgaggtggc 360
cgccggcatc tggggctttt tcaacaagga ccagatcgcc aaggatgtga agcagttcta 420
tgaccaggcc ctacagcagg ccgtggtgga tggatgacgcc aacaacgcac aggctgtgg 480
gaagacccctt caccgagacgc ttgactgctg tggctccagc acactgactg ctttgaccac 540
ctcagtgctc aagaacaatt tggatccctc gggcagcaac atcatcagca acctcttcaa 600
ggaggactgc caccagaaga tcgatgaccc tttctccggg aagctgtacc tcattggcat 660

tgctgccatc gtggtcgctg tgcgtatcatgt ctgcgagatg atccctgagca tggtgctgtg	720
ctgtggcatc cggAACAGCT ccgtgtactg aggccccgca gctctggcca caggAACACCTC	780
tgcagtggccc cctaagtgcac ccggacactt ccgagggggc catcaccgccc tgtgttatata	840
acgtttccgg tattactctg ctacacgttag cctttttact tttggggttt tgttttgtt	900
ctgaactttc ctgttacctt ttcaaggctg acgtcacatg taggtggcgt gtatgagtgg	960
agacgggcct gggctttggg gactggaggg caggggtcct tctgcccctgg ggtcccaggg	1020
tgctctgcct gctcagccag gcctctcctg ggagccactc gcccaGAGAC tcagcttggc	1080
caacttgggg ggctgtgtcc acccagccccg cccgtccctgt gggctgcaca gctcaccttg	1140
ttccctcctg ccccggttgc agagccgagt ctgtggcac tctctgcctt catgcacctg	1200
tcctttctaa cacgtgcct tcaactgtaa tcacaacatc ctgactccgt catttaataaa	1260
agaaggaaca tcaggcatgc taaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa	1320
aaaaaaaaaaa aa	1332

<210> 2
<211> 236
<212> PRT
<213> Homo sapiens

<400> 2

Phe Asn Phe Val Phe Trp Leu Ala Gly Gly Val Ile Leu Gly Val Ala
20 25 30

Leu Trp Leu Arg His Asp Pro Gln Thr Thr Asn Leu Leu Tyr Leu Glu
35 40 45

Leu Gly Asp Lys Pro Ala Pro Asn Thr Phe Tyr Val Gly Ile Tyr Ile
50 55 60

Leu Ile Ala Val Gly Ala Val Met Met Phe Val Gly Phe Leu Gly Cys
65 70 75 80

Tyr Gly Ala Ile Gln Glu Ser Gln Cys Leu Leu Gly Thr Phe Phe Thr
85 90 95

Cys Leu Val Ile Leu Phe Ala Cys Glu Val Ala Ala Gly Ile Trp Gly
100 105 110

Phe Val Asn Lys Asp Gln Ile Ala Lys Asp Val Lys Gln Phe Tyr Asp
115 120 125

Gln Ala Leu Gln Gln Ala Val Val Asp Asp Asp Ala Asn Asn Ala Lys
130 135 140

Ala Val Val Lys Thr Phe His Glu Thr Leu Asp Cys Cys Gly Ser Ser
145 150 155 160

Thr Leu Thr Ala Leu Thr Thr Ser Val Leu Lys Asn Asn Leu Cys Pro
165 170 175

Ser Gly Ser Asn Ile Ile Ser Asn Leu Phe Lys Glu Asp Cys His Gln
180 185 190

Lys Ile Asp Asp Leu Phe Ser Gly Lys Leu Tyr Leu Ile Gly Ile Ala
195 200 205

Ala Ile Val Val Ala Val Ile Met Ile Phe Glu Met Ile Leu Ser Met

4/4

210

215

220

Val Leu Cys Cys Gly Ile Arg Asn Ser Ser Val Tyr
225 230 235